Cancer or Tumor Profiling Market Size, Share, Trends, Industry Analysis Report: By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, and Others), Technology, Technique, Application, and Region (North America, Eu

The global cancer or tumor profiling market size is expected treach USD 35.36 billion by 2034, according ta new study by Polaris Market Research. The report “Cancer or Tumor Profiling Market Size, Share, Trends, Industry Analysis Report: By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, and Others), Technology, Technique, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight intcurrent market dynamics and provides analysis on future market growth.

The cancer or tumor profiling market expansion is driven by the increasing prevalence of cancer worldwide and the growing demand for personalized medicine. Key drivers include advancements in genomic technologies such as next-generation sequencing (NGS) and liquid biopsy, which enable early detection, better diagnosis, and more targeted treatments. Cancer or tumor profiling market opportunities exist in emerging markets, where rising healthcare access and awareness are boosting the adoption of cancer profiling technologies.

Trends such as the integration of artificial intelligence (AI) for data analysis and the growing focus on noninvasive diagnostic techniques are shaping the market. With ongoing innovations in biomarker discovery and regulatory support for precision diagnostics, the market is poised for continued expansion, with a heightened emphasis on improving patient outcomes through personalized and more effective treatment strategies.

Cancer or Tumor Profiling Market Report Highlights

The breast cancer segment, by cancer type, holds the largest cancer or tumor profiling market share due tits high prevalence and the growing demand for personalized treatments and genomic profiling. However, the lung cancer segment is registering the highest growth due tthe increasing use of liquid biopsy and advanced genomic profiling for early detection and targeted therapies.

By technology, the next-generation sequencing (NGS) segment dominates the market, offering comprehensive insights inttumor genetic profiles and driving precision oncology. The polymerase chain reaction (PCR) segment is the fastest-growing technology segment, fueled by its cost-effectiveness and application in liquid biopsy for early cancer detection.

The genomics segment, based on technique, leads the cancer or tumor profiling market revenue share due tits ability tprovide in-depth molecular data on mutations, gene expressions, and tumor heterogeneity, which are critical for personalized medicine. The epigenetics segment is experiencing the highest growth, driven by its role in uncovering molecular mechanisms that drive cancer progression and response ttreatment.

In terms of application, the personalized medicine segment dominates the market, as more oncologists adopt genomic and biomarker-based testing tguide treatment decisions and improve patient outcomes. The biomarker discovery segment is growing rapidly as new and more precise biomarkers are being identified for early detection and monitoring of cancer progression.

North America holds the largest market share, supported by its advanced healthcare infrastructure and strong focus on precision oncology. Asia Pacific is the fastest-growing market, driven by increasing healthcare access, rising cancer rates, and expanding adoption of cancer profiling technologies.

Polaris Market Research has segmented the cancer or tumor profiling market report on the basis of cancer type, technology, technique, application, and region:

By Cancer Type Outlook (Revenue – USD Billion, 2020–2034)

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Melanoma Cancer

Others

By Technology Outlook (Revenue – USD Billion, 2020–2034)

Next-Generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

In-Situ Hybridization (ISH)

Microarray

Others

By Technique Outlook (Revenue – USD Billion, 2020–2034)

Genomics

Proteomics

Epigenetics

Metabolomics

By Application Outlook (Revenue – USD Billion, 2020–2034)

Personalized Medicine

Diagnostics

Biomarker Discovery

Prognostics

Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America